Recent 8-K filings for PBSV
Highest-materiality recent filing
Pharma-Bio Serv FY2024 rev $9.5M (-$7.5M YoY), net loss $0.8M; declares $0.075 special dividend
- Revenue for year ended Oct 31, 2024 approximately $9.5M, a decrease of $7.5M from prior year.
- Net loss of approximately $0.8M compared to net income of $1.3M in the prior year.
-
Pharma-Bio Serv Q1 revenue $2.7M, net income $0.2M; both up YoY
Three-month revenue $2.7M, up $0.3M vs prior year; net income $0.2M, up $0.1M.
-
Pharma-Bio Serv annual meeting elects Irving Wiesen as Class I director
Irving Wiesen elected with 10,208,071 votes for and 195,625 withheld; 2,839,645 broker non-votes.
-
Pharma-Bio Serv Q1 revenue $2.3M, net income $32,860
Revenue of approx. $2.3M, down ~$0.2M from prior year quarter.
-
Revenue $9.0M, decrease of $0.5M YoY; net loss $0.1M, improvement of $0.7M from prior year.
-
Pharma-Bio Serv Q3 revenue $2.0M (down 17% YoY); net loss narrows to $0.2M
Revenue for three months ended July 31, 2025 was $2.0M, down from $2.4M in the same period last year.
-
Pharma-Bio Serv reports Q2 net income of $0.1M, reversing prior-year loss
Q2 revenue $2.4M (vs $2.3M YoY); six-month revenue $4.9M (vs $4.8M YoY).
-
Pharma-Bio Serv annual meeting elects Howard Spindel, approves say on pay every three years
Howard Spindel elected Class III director with 7,265,978 votes for, 2,359,070 withheld; 3,264,532 broker non-votes.
-
Pharma-Bio Serv reports Q1 revenue of $2.5M, near breakeven net income
Revenue for quarter ended Jan 31, 2025 was ~$2.5M, up ~$0.1M YoY.
-
Pharma-Bio Serv declares special dividend of $0.075/share payable March 20, 2025
Special dividend of $0.075 per share approved by the Board of Directors.
-
Pharma-Bio Serv FY2024 rev $9.5M (-$7.5M YoY), net loss $0.8M; declares $0.075 special dividend
Revenue for year ended Oct 31, 2024 approximately $9.5M, a decrease of $7.5M from prior year.
-
Pharma-Bio Serv Q3 revenue falls to $2.4M, swings to net loss of $0.3M
Q3 revenue $2.4M, down ~$2.2M (48%) from $4.6M in same quarter last year.
-
Pharma-Bio Serv Q2 revenue down 48% to $2.4M; net loss $0.2M vs income $0.4M
Q2 revenue $2.4M, decline of $2.2M from $4.6M in prior-year quarter.
-
Stockholders approve extension of long-term incentive plan to 2034; re-elect two directors
Stockholders approved extending the 2014 Long-Term Incentive Plan term to March 31, 2034.
-
Pharma-Bio Serv Q1 revenue down 44% to $2.4M; swings to net loss of $270.7K
Revenue for Q1 ended Jan 31, 2024: $2.4M, down $1.9M from $4.3M in prior-year quarter.
-
Revenue of $17.0M, down $2.4M YoY; net income of $1.3M, up $0.3M YoY.
-
Pharma-Bio Serv declares special dividend of $0.075 per share, payable Feb 15, 2024
Board approved a special dividend of $0.075 per share.
-
Pharma-Bio Serv Q3 net income up $0.2M to $0.5M; revenue down $0.2M to $4.6M
Net income for Q3 FY2023 (three months ended July 31) was approx $0.5M, up from $0.3M YoY; nine-month net income $1.4M vs $0.9M.
-
Pharma-Bio Serv Q2 net income rises to $0.4M; revenue falls 8% to $4.6M
Revenue for three months ended Apr 30, 2023: $4.6M, down $0.4M YoY.
-
Pharma-Bio Serv elects Irving Wiesen as Class I director at 2023 annual meeting
Irving Wiesen elected Class I director with 7,477,036 for and 11,696,947 withheld; 515,852 broker non-votes.
-
Pharma-Bio Serv Q1 2023 revenue $4.2M (-$0.8M YoY); net income $0.4M (+$0.1M YoY)
Quarterly revenue $4.2M, down from $5.0M in prior-year quarter.
-
Pharma-Bio Serv declares special dividend of $0.075 per share
Special dividend of $0.075 per share approved by Board of Directors.
-
Pharma-Bio Serv adopts amended bylaws adding advance notice, supermajority vote requirement
Advance notice bylaw established as exclusive means for stockholder proposals and nominations.
-
Pharma-Bio Serv retains ACP Capital Markets for M&A advisory and investment banking
Retained ACP Capital Markets LLC for investment banking and M&A advisory services.
-
Pharma-Bio Serv FY2022 net income $1.0M, up from prior loss; revenue $19.4M down 3.5%
Revenue for FY ended Oct 31, 2022: ~$19.4M, down ~$0.7M from prior year.
-
Pharma-Bio Serv Q3 revenue $4.8M, net income $0.3M down $2M YoY on SBA loan forgiveness
Revenue for Q3 ended July 31, 2022: $4.8M, down $0.2M YoY; 9-month revenue $14.8M, up $0.2M.
-
Howard Spindel elected Class III director with 13,636,564 votes for, 2,101 withheld; 2,639,780 broker non-votes.
-
Pharma-Bio Serv Q2 FY2022 revenue $5.0M, net income $0.2M; stable YoY
Revenue for Q2 ended April 30, 2022 was ~$5.0M, up ~$0.1M from prior-year quarter.
-
Pharma-Bio Serv Q1 revenue rises to $5.0M; net income flat at $0.3M
Revenue of $5.0M, up ~$0.5M YoY; net income unchanged at ~$0.3M.
-
Pharma-Bio Serv revenues fall to $20.1M, posts $2.1M net loss; declares $0.075 special dividend
FY 2021 revenue $20.1M, down ~$1.4M YoY; net loss $2.1M vs. prior-year net income of $2.0M.
-
Pharma-Bio Serv declares $0.075 special dividend payable January 3, 2022
Board declared a special cash dividend of $0.075 per share.
-
Pharma-Bio Serv resumes stock repurchase program with 1.66M shares authorized
Company resumed stock repurchase program on September 24, 2021.
-
Pharma-Bio Serv Q3 revenue falls 20.5% YoY; net income boosted by $1.96M PPP forgiveness
Revenue for Q3 $4.99M, down 20.5% YoY from $6.28M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.50 · Most common event earnings